Clinical Trials Directory

Trials / Sponsors / Janssen Biotech, Inc.

Janssen Biotech, Inc.

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
Active Not RecruitingAn Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative
Ulcerative Colitis
—2016-12-16
TerminatedA Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Hav
Arthritis, Rheumatoid
Phase 32013-10-01
CompletedA Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-
Psoriasis
Phase 32012-03-01
CompletedAn Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psori
Moderate to Severe Plaque Psoriasis
—2011-06-01
CompletedIMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Prostate Cancer, Prostatic Neoplasm
Phase 22011-05-04
TerminatedA Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Dis
Crohn's Disease
Phase 32010-11-01
CompletedUstekinumab Safety and Surveillance Program Using the Ingenix NHI Database
Psoriasis
—2010-02-09
CompletedGolimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimuma
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Phase 32009-12-01
CompletedGolimumab Safety and Surveillance Program Using the Ingenix NHI Database
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis
—2009-04-14
Active Not RecruitingA Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Di
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
—2007-05-31
CompletedAnalysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Di
Inflammatory Bowel Disease
—2007-01-01
CompletedThe Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry
Crohn's Disease
—1999-08-01
Approved For MarketingAn Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphom
Relapsed or Refractory Mantle Cell Lymphoma
——